Publication Name	World Journal of Gastroenterology
Manuscript ID	15824
Country	China

Received	2014-12-11 08:48
Peer-Review Started	2014-12-11 16:39
First Decision by Editorial Office Director
Return for Revision	2015-01-05 17:22
Revised	2015-01-09 09:50
Publication Fee Transferred
Second Decision by Editor	2015-02-10 21:28
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2015-02-11 15:59
Articles in Press	2015-02-11 16:22
Edit the Manuscript by Language Editor	2015-03-11 18:14
Typeset the Manuscript	2015-04-25 15:36
Publish the Manuscript Online	2015-05-18 17:02

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
Manuscript Source	Invited Manuscript
All Author List	Xing-Shun Qi, Xiao-Zhong Guo, Guo-Hong Han, Hong-Yu Li and Jiang Chen
Funding Agency and Grant Number
Corresponding Author	Xiao-Zhong Guo, MD, PhD, Professor, Department of Gastroenterology, General Hospital of Shenyang Military Area, No. 83 Wenhua Road, Shenyang 110840, Liaoning Province, China. guo_xiao_zhong@126.com
Key Words	MET; Hepatocyte growth factor; Tivantinib; Cabozantinib; INC280; MSC2156119J; Golvatinib; Foretinib
Core Tip	MET inhibitors are being tested as the first-line or second-line therapy for advanced hepatocellular carcinoma after the failure of a loco-regional or systemic therapy, especially in patients with high MET expression. Ongoing phase Ⅲ randomized controlled trials will provide the decisive recommendations regarding the use of MET inhibitors in advanced hepatocellular carcinoma.
Publish Date	2015-05-18 17:02
Citation	Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015; 21(18): 5445-5453
URL	http://www.wjgnet.com/1007-9327/full/v21/i18/5445.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i18.5445

Full Article (PDF)	WJG-21-5445.pdf
Full Article (Word)	WJG-21-5445.doc
Manuscript File	15824-Review.doc
Answering Reviewers	15824-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15824-Conflict-of-interest statement.pdf
Copyright License Agreement	15824-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	15824-Language certificate.pdf
Peer-review Report	15824-Peer-review(s).pdf
Scientific Misconduct Check	15824-Scientific misconduct check.pdf
Scientific Editor Work List	15824-Scientific editor work list.pdf